An Open Trial of Cysteamine Treatment in Schizophrenia
| Status: | Archived |
|---|---|
| Conditions: | Schizophrenia, Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | September 2009 |
| End Date: | June 2011 |
The purpose of this study is to determine the tolerability of the medication cysteamine on
schizophrenia patients and to evaluate the effect of the medication on the symptoms of
schizophrenia.
Despite the availability of numerous antipsychotics, the treatment of schizophrenia is very
unsatisfactory. Many patients have persistent positive psychotic symptoms or negative
symptoms despite treatment, and any improvement in cognitive function is small. New
approaches to the pharmacotherapy of schizophrenia that are not based primarily on
dopaminergic blockade are needed.
The rationale for a trial of cysteamine comes from the evidence that cysteamine increases
brain concentrations of brain-derived neurotrophic factor.
We will conduct an open-label study of tolerability and efficacy of cysteamine as an adjunct
to second-generation antipsychotics in schizophrenia and schizoaffective subjects with
partially responsive symptoms.
Our objectives are to determine the safety and tolerability of cysteamine administered as an
adjunct to second-generation antipsychotic drugs in adult outpatients with
partially-responsive schizophrenia. Additionally, we are evaluating the effect of
cysteamine on the positive and negative symptoms of schizophrenia as measured by changes in
the Positive and Negative Symptom Scale (PANSS), and on cognitive impairment as measured by
the Brief Assessment of Cognition in Schizophrenia (BACS).
We found this trial at
1
site
Med College of Georgia Georgia Regents University, home of the Medical College of Georgia, is...
Click here to add this to my saved trials
